ArticleProceedings of the National Academy of Sciences of the United States of America1987
Expression and rearrangement of the ROS1 gene in human glioblastoma cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1987. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 223 citations in OpenAlex.
- Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.The oncologist · 2016Trial
- Prognostic value of ROS1 rearrangement in lung adenocarcinoma stratified by clinicopathologic and radiological features: a retrospective cohort study.Translational lung cancer research · 2026Article
- Clustering and a conformational switch drive activation of the mammalian receptor tyrosine kinase ROS1.Nature communications · 2026Article
- Review
- Recombination between fragile regions associated with chromosomal rearrangements in glioblastoma can be mediated by RAGs.iScience · 2025Article
- Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions.Cancer · 2025Review
- Identification of the clinical and genetic characteristics of gliomas with gene fusions by integrated genomic and transcriptomic analysis.European journal of medical research · 2025Article
- Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024Review
- Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Thoracic cancer · 2024Article
- Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.Cancer medicine · 2024Review
- Targeted therapeutic options in early and metastatic NSCLC-overview.Pathology oncology research : POR · 2024Review
- KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway.Cancers · 2023Article
- Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Analysis of CD74 Occurrence in Oncogenic Fusion Proteins.International journal of molecular sciences · 2023Review
- Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.BMC cancer · 2023Article
- To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.Journal of cancer research and clinical oncology · 2023Review
- Routine Clinically Detected IncreasedJTO clinical and research reports · 2023Article
- Importance ofCancer drug resistance (Alhambra, Calif.) · 2023Review
- ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.International journal of cancer · 2022Article
- Comparison of ROS1-rearrangement detection methods in a cohort of surgically resected non-small cell lung carcinomas.Translational lung cancer research · 2022Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human ROS1 gene, which possibly encodes a growth factor receptor, was found to be expressed in human tumor cell lines. In a survey of 45 different human cell lines, we found ROS1 to be expressed in glioblastoma-derived cell lines at high levels and not to be expressed at all, or expressed at very low levels, in the remaining cell lines. The ROS1 gene was present in normal copy numbers in all cell lines that expressed the gene. However, in one particular glioblastoma line, we detected a potentially activating mutation at the ROS1 locus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.